In the pooled population , treatment with levomilnacipran ER versus placebo resulted in greater improvement in MADRS score ( -15.8 versus -12.9 ; LS mean difference , -2.9 ; P < .001 ) and higher response rates ( 44.7 % versus 34.5 % ; P < .001 ) .